Francesco Giansanti

Dr. Francesco Giansanti

Life, Health and Environmental Sciences
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2016 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Francesco GiansantiFrancesco Giansanti
Francesco Giansanti
GPGloria Panella
Gloria Panella
LLLoris Leboffe
Loris Leboffe
Antonini GiovanniAntonini Giovanni
Antonini Giovanni
Lactoferrin is an iron-binding protein present in large quantities in colostrum and in breast milk, in external secretions and in polymorphonuclear leukocytes. Lactoferrin’s main function is non-immune protection. Among several protective activities shown by lactoferrin, those displayed by orally administered lactoferrin are: (i) antimicrobial activity, which has been presumed due to iron deprivation, but more recently attributed also to a specific interaction with the bacterial cell wall and extended to viruses and parasites; (ii) immunomodulatory activity, with a direct effect on the development of the immune system in the newborn, together with a specific antinflammatory effects; (iii) a more recently discovered anticancer activity. It is worth noting that most of the protective activities of lactoferrin have been found, sometimes to a greater extent, also in peptides derived from limited proteolysis of lactoferrin that could be generated after lactoferrin ingestion. Lactoferrin could therefore be considered an ideal nutraceutic product because of its relatively cheap production from bovine milk and of its widely recognized tolerance after ingestion, along with its well demonstrated protective activities. The most important protective activities shown by orally administered bovine lactoferrin are reviewed in this article.

Verified
Journal Article
Open access
PDF file
SPSara Ponziani
Sara Ponziani
GVGiulia Di Vittorio
Giulia Di Vittorio
GPGiuseppina Pitari
Giuseppina Pitari
ACAnnamaria Cimini
Annamaria Cimini
Matteo ArdiniMatteo Ardini
Matteo Ardini
Francesco GiansantiFrancesco Giansanti
Francesco Giansanti
In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a drug with cytotoxic activity cross-linked to a monoclonal antibody, targeting antigens expressed at higher levels on tumor cells than on normal cells. By providing a selective targeting mechanism for cytotoxic drugs, ADCs improve the therapeutic index in clinical practice. In this review, the chemistry of ADC linker conjugation together with strategies adopted to improve antibody tolerability (by reducing antigenicity) are examined, with particular attention to ADCs approved by the regulatory agencies (the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)) for treating cancer patients. Recent developments in engineering Immunoglobulin (Ig) genes and antibody humanization have greatly reduced some of the problems of the first generation of ADCs, beset by problems, such as random coupling of the payload and immunogenicity of the antibody. ADC development and clinical use is a fast, evolving area, and will likely prove an important modality for the treatment of cancer in the near future.

1 March 2012 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
Francesco GiansantiFrancesco Giansanti
Francesco Giansanti
LLLoris Leboffe
Loris Leboffe
GPGiuseppina Pitari
Giuseppina Pitari
Rodolfo IppolitiRodolfo Ippoliti
Rodolfo Ippoliti
Antonini GiovanniAntonini Giovanni
Antonini Giovanni

1 October 2001 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
FSFabiana Superti
Fabiana Superti
Rosa Anna SicilianoRosa Anna Siciliano
Rosa Anna Siciliano
BRBarbara Rega
Barbara Rega
Francesco GiansantiFrancesco Giansanti
Francesco Giansanti
Piera ValentiPiera Valenti
Piera Valenti
Antonini GiovanniAntonini Giovanni
Antonini Giovanni

1 February 2002 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
PRPaola Rossi
Paola Rossi
Francesco GiansantiFrancesco Giansanti
Francesco Giansanti
ABAlberto Boffi
Alberto Boffi
MAMaria Ajello
Maria Ajello
Piera ValentiPiera Valenti
Piera Valenti
Antonini GiovanniAntonini Giovanni
Antonini Giovanni
Bovine lactoferrin (bLf) is known to damage the outer membrane of Gram-negative bacteria by binding to bacterial lipopolysaccharide (LPS). We report that LPS is released from bacterial outer membranes also when apo- or metal-saturated Lf is separated from bacterial cells by a dialysis membrane. This process occurs in phosphate-buffered saline with no added Ca2+ and Mg2+ and is hindered by addition of these cations. The effect of bLf is similar to that induced by EDTA and has been ascribed to chelation of Ca2+. In fact, it may be envisaged that Ca2+-binding sites on LPS have different affinities and that bLf can remove those ions that are more weakly bound. Ca2+ binding does not alter Lf iron-binding properties significantly or its UV and CD spectral features but brings about changes in the FT-IR bands due to carboxylate residues. Ca2+ binding is characterized by an apparent dissociation constant of 6 µM and a stoichiometry of 1.55 Ca2+ per Lf molecule; it enhances bLf stability towards chemical and thermal denaturation. The increase in stability takes place in both the apo- and iron-saturated forms but not in the desialilated protein, indicating that the carboxylate groups of the sialic acid residues present on two of the glycan chains are involved in Ca2+ binding.Key words: lactoferrin, calcium, antibacterial activity, lipopolysaccharides, protein stability, denaturation.

1 February 2002 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
Francesco GiansantiFrancesco Giansanti
Francesco Giansanti
PRPaola Rossi
Paola Rossi
MMMaria Teresa Massucci
Maria Teresa Massucci
DBDario Botti
Dario Botti
Antonini GiovanniAntonini Giovanni
Antonini Giovanni
LSLucilla Seganti
Lucilla Seganti
Ovotransferrin (formerly conalbumin) is an iron-binding protein present in birds. It belongs to the transferrin family and shows about 50% sequence homology with mammalian serum transferrin and lactoferrin. This protein has been demonstrated to be capable of delivering iron to cells and of inhibiting bacterial multiplication. However, no antiviral activity has been reported for ovotransferrin, although the antiviral activity of human and bovine lactoferrins against several viruses, including human herpes simplex viruses, has been well established. In this report, the antiviral activity of ovotransferrin towards chicken embryo fibroblast infection by Marek's disease virus (MDV), an avian herpesvirus, was clearly demonstrated. Ovotransferrin was more effective than human and bovine lactoferrins in inhibiting MDV infection and no correlation between antiviral efficacy and iron saturation was found. The observations reported here are of interest from an evolutionary point of view since it is likely that the defensive properties of transferrins appeared early in evolution. In birds, the defensive properties of ovotransferrin remained joined to iron transport functions; in mammals, iron transport functions became peculiar to serum transferrin, and the defensive properties towards infections were optimised in lactoferrin.Key words: ovotransferrin, lactoferrin, Marek disease's virus, herpes simplex virus, evolution.